Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors. The company was founded in 2002 and is based in Bedminster, New Jersey. As of April 2, 2025, Intra-Cellular Therapies, Inc. operates as a subsidiary of Johnson & Johnson Innovative Medicine.
CAPLYTA's Triumph | Explore CAPLYTA's market success, driving Intra-Cellular Therapies' growth with Q3 revenue of $175.2 million and potential to reach $5 billion in mood disorders |
Patent Predicament | Delve into the complex patent landscape, balancing extended protection until 2034 against potential challenges from generic competitors |
Pipeline Promise | Discover Intra-Cellular's strategic pipeline developments, including long-acting injectables and ITI-1284, diversifying beyond CAPLYTA |
Market Momentum | Analyst targets range from $96 to $135, reflecting optimism in CAPLYTA's expansion and Intra-Cellular's robust financial performance |
Metrics to compare | ITCI | Peers Peers - average of corresponding metrics from companies closely matching ITCI: | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipITCIPeersSector |
---|---|---|---|---|
P/E Ratio | 0.0x | 0.0x | 0.0x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 0.0x | 0.0x | 0.0x | |
Price / LTM Sales | 0.0x | 0.0x | 0.0x | |
Upside (Analyst Target) | 0.0% | 0.0% | 0.0% | |
Fair Value Upside | Unlock | 0.0% | 0.0% | Unlock |